Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder~* experiencing a current major depressive episode~* treatment with either lithium or valproate and inadequate therapeutic response of depressive symptoms~Exclusion Criteria:~* any subject unable to provide informed consent~* any female subject who is pregnant or breastfeeding~* any subject judged to be medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone 28 mg (ITI-007 40 mg tosylate) (Type: EXPERIMENTAL): Lumateperone 28 mg (ITI-007 40 mg tosylate) administered orally as capsules once daily for 6 weeks
- Lumateperone 42 mg (ITI-007 60 mg tosylate) (Type: EXPERIMENTAL): Lumateperone 42 mg (ITI-007 60 mg tosylate) administered orally as capsules once daily for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally as visually-matched capsules once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).